Aprea Therapeutics, Inc. (APRE)
0.80
-0.01
(-0.78%)
USD |
NASDAQ |
Sep 04, 14:02
Aprea Therapeutics Research and Development Expense (TTM) : 6.721M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.721M |
| March 31, 2026 | 6.171M |
| December 31, 2025 | 7.043M |
| September 30, 2025 | 8.393M |
| June 30, 2025 | 9.601M |
| March 31, 2025 | 10.25M |
| December 31, 2024 | 9.364M |
| September 30, 2024 | 9.050M |
| June 30, 2024 | 8.326M |
| March 31, 2024 | 7.971M |
| December 31, 2023 | 7.628M |
| September 30, 2023 | 6.113M |
| June 30, 2023 | 5.108M |
| Date | Value |
|---|---|
| March 31, 2023 | 9.717M |
| December 31, 2022 | 12.55M |
| September 30, 2022 | 16.48M |
| June 30, 2022 | 21.38M |
| March 31, 2022 | 21.22M |
| December 31, 2021 | 23.90M |
| September 30, 2021 | 28.76M |
| June 30, 2021 | 31.51M |
| March 31, 2021 | 35.55M |
| December 31, 2020 | 37.88M |
| September 30, 2020 | 36.59M |
| June 30, 2020 | 32.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Zymeworks, Inc. | 128.70M |
| Rhythm Pharmaceuticals, Inc. | 173.01M |
| Onconetix, Inc. | 0.0753M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |